EA201490538A1 - Лечение кашля и его приступов - Google Patents

Лечение кашля и его приступов

Info

Publication number
EA201490538A1
EA201490538A1 EA201490538A EA201490538A EA201490538A1 EA 201490538 A1 EA201490538 A1 EA 201490538A1 EA 201490538 A EA201490538 A EA 201490538A EA 201490538 A EA201490538 A EA 201490538A EA 201490538 A1 EA201490538 A1 EA 201490538A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cough
treatment
attractions
anion
coughing episodes
Prior art date
Application number
EA201490538A
Other languages
English (en)
Inventor
Майкл Дж.А. Уолкер
Original Assignee
Верона Фарма Плк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Верона Фарма Плк filed Critical Верона Фарма Плк
Publication of EA201490538A1 publication Critical patent/EA201490538A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Данное изобретение направлено на каркаиний в форме соли с анионом An, где Anпредставляет собой анион фармацевтически приемлемой кислоты, для применения в лечении и/или подавлении у пациента кашля, приступов кашля или эпизодов кашля.
EA201490538A 2011-09-06 2012-09-06 Лечение кашля и его приступов EA201490538A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531432P 2011-09-06 2011-09-06
PCT/GB2012/052190 WO2013034909A1 (en) 2011-09-06 2012-09-06 Treating cough and tussive attacks

Publications (1)

Publication Number Publication Date
EA201490538A1 true EA201490538A1 (ru) 2014-08-29

Family

ID=46845779

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490538A EA201490538A1 (ru) 2011-09-06 2012-09-06 Лечение кашля и его приступов

Country Status (14)

Country Link
US (1) US20140242174A1 (ru)
EP (1) EP2753323A1 (ru)
JP (1) JP2014525471A (ru)
KR (1) KR20140069091A (ru)
CN (1) CN103974699A (ru)
AU (1) AU2012306076A1 (ru)
CA (1) CA2847817A1 (ru)
EA (1) EA201490538A1 (ru)
GB (3) GB2499559B8 (ru)
IL (1) IL231301A0 (ru)
MX (1) MX2014002675A (ru)
SG (1) SG11201400325WA (ru)
WO (2) WO2013034910A1 (ru)
ZA (1) ZA201401658B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
US20150224077A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
JP6701086B2 (ja) * 2014-02-20 2020-05-27 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤
KR20170003926A (ko) * 2014-04-08 2017-01-10 산사 코포레이션 (바베이도스) 인코포레이티드 니코틴 제형 및 이의 제조방법
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US20170071248A1 (en) 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB995256A (en) 1961-02-20 1965-06-16 Astra Apotekarnes Kem Fab Quaternary ammonium salts having anti-arrhythmic activity
JP2002517438A (ja) 1998-06-09 2002-06-18 ノートラン・ファーマシューティカルズ・インコーポレーテッド 咳の治療のための組成物及び方法
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them

Also Published As

Publication number Publication date
GB2499559B (en) 2014-03-26
US20140242174A1 (en) 2014-08-28
SG11201400325WA (en) 2014-03-28
WO2013034909A1 (en) 2013-03-14
IL231301A0 (en) 2014-04-30
GB201304501D0 (en) 2013-04-24
KR20140069091A (ko) 2014-06-09
GB201304499D0 (en) 2013-04-24
WO2013034910A1 (en) 2013-03-14
GB201311021D0 (en) 2013-08-07
GB2499559B8 (en) 2014-04-02
GB2499559A (en) 2013-08-21
MX2014002675A (es) 2014-04-25
JP2014525471A (ja) 2014-09-29
ZA201401658B (en) 2015-04-29
EP2753323A1 (en) 2014-07-16
AU2012306076A1 (en) 2014-03-20
CN103974699A (zh) 2014-08-06
CA2847817A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
EA201490538A1 (ru) Лечение кашля и его приступов
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
IN2014DN09434A (ru)
EP2702994A3 (en) Methods of administering pirfenidone therapy
EA201300989A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2011011109A (es) Formulaciones orales de bendamustina.
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
EA201600318A1 (ru) Циклические тиеноурацилкарбоксамиды и их применение